The global market for Biological Drugs was estimated at US$345.3 Billion in 2023 and is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive ...

The following is a summary of “Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study,” ...

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site. Financing from OrbiMed, Novo Holdings, Jeito Capital, and others ...

For those on a biologic, the most potential for a problem with infection is believed to be when a patient is immunosuppressed from another medication such as methotrexate, hydroxyurea ...

Beyfortus is a biologic drug, which means it’s made from parts of living organisms. It doesn’t come in a biosimilar form. Biosimilars are like generic drugs. Unlike generics, which are made ...

Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved ...

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.